Bangalore,
Jan 5 : Pharmed, one of India’s fastest-growing
pharmaceutical companies, along with the Indian Orthopaedic Association’s (IOA)
Osteoporosis Council recently unveiled the Indian Osteoporosis Guidelines 2025
at IOACON 2025 in Guwahati. The Indian Orthopaedic Association Guidelines for
Osteoporosis 2025 have been published in the Indian Journal of Orthopaedics,
the official journal of the IOA, underscoring their scientific credibility and
national relevance.
The
newly released guidelines provide a structured, evidence-based, and practical
framework for the prevention, early diagnosis, and management of osteoporosis.
They are intended for a wide range of healthcare professionals, including
orthopaedic surgeons, physicians, specialists, nurses, and allied healthcare providers
involved in osteoporosis care.
Developed
using a robust Delphi consensus methodology, the guidelines represent the
collective expertise of 62 nationally recognised osteoporosis and bone health
experts from across India. The expert panel comprised leading clinicians,
researchers, and academicians, including Dr Ramesh Sen, Dr Shiva Shankar Jha,
Dr S. S. Amarnath, Dr Jawahar T. Jethwa, Dr Jai Prakash Tiwari, Dr Chinmoy Das,
Dr Srinivas Kambhampati, Dr Murali Poduval, Dr Bharatkumar R. Dave, Dr Ram Chaddha,
Dr Karthik Vishwanathan, Dr S. Chandrashekara, Dr Renuka Panchagnula, and Dr
Sanjay Bhadada, among others.
The
development process involved six structured rounds of questionnaires, ensuring
scientific rigour, transparency, and alignment with current clinical evidence.
This systematic approach ensures that the guidelines reflect current best
practices and expert consensus, while remaining adaptable to evolving
scientific knowledge over the next five to six years.
Commenting
on the significance of the release, Dr Amarnath, Orthopaedic Surgeon and
Chairman – Indian Osteoporosis Council of the IOA, said, “The development of
the Indian Osteoporosis Guidelines 2025 was a rigorous and highly collaborative
effort involving experts from across the country. Through multiple structured
rounds of consensus, in-depth deliberations, and careful evaluation of
available evidence, the panel worked to ensure that the recommendations are
both scientifically sound and practical for day-to-day clinical use. Our shared
objective was to create guidelines that truly assist doctors in delivering
consistent and effective osteoporosis care within the Indian healthcare
setting.”
Highlighting
the academic and clinical importance of the initiative, Dr Srinivas
Kambhampati, Orthopaedic Surgeon and Editor-in-Chief, Indian Journal of
Orthopaedics, stated, “Osteoporosis continues to pose a significant and
growing challenge in India, particularly with an ageing population and rising
fracture risk. These guidelines provide clinicians with a clear,
evidence-based, and context-specific framework that supports informed
decision-making in screening, diagnosis, and management. Their publication in
the Indian Journal of Orthopaedics reflects both the academic rigour of the
process and their value as a long-term reference for practising doctors and
researchers alike.”
With
a legacy spanning more than seven decades, Pharmed continues to focus on
evidence-based speciality healthcare solutions aimed at improving patient
outcomes and quality of life. Its association with the guidelines reflects its
long-standing commitment to advancing bone and joint health under the guiding
philosophy of ‘making bones and joints the heart of our profession.’
Speaking
on Pharmed’s role, Dr Jayanta Jana, Senior Executive Vice President – Medical,
Regulatory Affairs, and Business Alliances, said, “At Pharmed, we believe
that meaningful progress in bone health begins with strong scientific
foundations. By supporting the Indian Osteoporosis Council for the release of
the Indian Osteoporosis Guidelines 2025, we reaffirm our commitment to
evidence-based care, preventive healthcare strategies, and long-term engagement
with the medical fraternity.”
Beyond
its therapeutic portfolio, Pharmed has been actively driving patient awareness
and early detection initiatives through the India Bone Health Initiative
(IBHI). Through nationwide Bone Mineral Density (BMD) screening camps, IBHI
facilitates early diagnosis and improves access to osteoporosis education. In
collaboration with doctors and healthcare institutions, the initiative has
reached lakhs of individuals across India, contributing to timely screening,
informed treatment decisions, and preventive bone healthcare.
Through
sustained efforts in clinical collaboration, medical education, and patient
outreach, Pharmed continues to support the development of a healthcare
ecosystem where bone health is prioritised, awareness is widespread, and
preventive care is integrated into routine clinical practice.
